Inhibiting TAK1 for CAR T cell-induced neurotoxicity

Inhibiting TAK1, a pro-inflammatory kinase activated by cytokines, could help treat neurotoxicity after CAR T cell treatment by inhibiting microglial  activation and subsequent neurocognitive defects. 

Microglia isolated from lymphoma patients treated with CD19-targeted CAR T cells had increased mRNA and protein expression of activation markers compared with microglia from individuals without lymphoma that were not treated with CAR T cells.  ...